Literature DB >> 1521032

Increased cotinine elimination and cotinine-N-oxide formation by phenobarbital induction in rat and mouse.

H Foth1, J Aubrecht, M Höhne, U I Walther, G F Kahl.   

Abstract

The metabolic fate of cotinine, the major metabolite of nicotine, was studied in phenobarbital-induced and non-induced isolated perfused rat lung and liver and in isolated hepatocytes of rats and mice. The non-induced lung tissue showed low cotinine metabolizing capacity while the perfused liver was approximately four times more active. After phenobarbital pretreatment the metabolism of cotinine was increased eight-fold in the intact liver. A substantial increase in cotinine metabolism was also found in isolated hepatocytes from PB-induced rats and in cultured mouse hepatocytes grown in a medium supplemented with PB. This was paralleled by an increased formation of cotinine-N-oxide which could be inhibited by 100 microM metyrapone. In contrast, the pulmonary elimination of cotinine was not affected by PB. A dominant role of primary N-oxidation of nicotine compared to C-oxidation was apparent in non-induced rat liver. After PB treatment the rate of nicotine-N'-oxide formation dropped markedly while the cotinine related pathways were increased causing an inversion of the N- to C-oxidation ratio. In the lung, cotinine formation was the preferred metabolic pathway of nicotine already in non-induced organs. The pattern of nicotine metabolites was not altered by PB induction. In conscious PB-induced rats receiving nicotine orally or intravenously, 3'-hydroxycotinine was found as the main urinary metabolite of nicotine while only a small fraction was excreted as cotinine-N-oxide. This discrepancy between the profile of nicotine metabolites in perfused liver and lung and in the urine in vivo indicates that extrahepatic organs other than the lung may be important sites of cotinine metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1521032     DOI: 10.1007/bf00184648

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  32 in total

1.  Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure.

Authors:  M J Jarvis; M A Russell; N L Benowitz; C Feyerabend
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

Review 2.  Future trends in the pharmacological treatment of smoking cessation.

Authors:  A H Glassman; L S Covey
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

3.  Structure of hydroxycotinine, a nicotine metabolite.

Authors:  E Dagne; N Castagnoli
Journal:  J Med Chem       Date:  1972-04       Impact factor: 7.446

4.  Nicotine metabolism in isolated perfused lung and liver of phenobarbital- and benzoflavone-treated rats.

Authors:  H Foth; H Looschen; H Neurath; G F Kahl
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

Review 5.  Clinical pharmacokinetics of nicotine.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

6.  Cotinine disposition and effects.

Authors:  N L Benowitz; F Kuyt; P Jacob; R T Jones; A L Osman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

7.  Nicotine pharmacokinetics and its application to intake from smoking.

Authors:  C Feyerabend; R M Ings; M A Russel
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

8.  Expression of cytochromes P-450c and P-450d mRNAs in cultured rat hepatocytes. 3-Methylcholanthrene induction is regulated primarily at the post-transcriptional level.

Authors:  G Silver; K S Krauter
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

9.  The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung.

Authors:  D E Williams; M K Shigenaga; N Castagnoli
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

10.  Gluconeogenesis in the perfused rat liver.

Authors:  R Hems; B D Ross; M N Berry; H A Krebs
Journal:  Biochem J       Date:  1966-11       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.